CCP
UTHR icon

Corient Capital Partners’s United Therapeutics UTHR Stock Holding History

Corient Capital Partners’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$219K Hold
930
– – 0.02% 585
2022
Q2 		$219K Buy
+930
New +$189K 0.02% 596

Other funds holding UTHR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Corient Capital Partners's UTHR Position: Q3 2022 in Review

Corient Capital Partners held its United Therapeutics (UTHR) position steady in Q3 2022 at 930 shares worth $219K. The position accounts for 0.02% of the portfolio, ranked #585.

Corient Capital Partners first reported a position in UTHR in Q2 2022 and has held it in 2 quarters since. 461 funds tracked by Wall St. Rank hold UTHR as of Q3 2022.

  • Corient Capital Partners held 930 shares of United Therapeutics worth $219K as of Q3 2022.
  • Corient Capital Partners left its United Therapeutics share count unchanged in Q3 2022.
  • United Therapeutics made up 0.02% of Corient Capital Partners's portfolio in Q3 2022, its #585 holding.
  • Corient Capital Partners first reported a position in United Therapeutics in Q2 2022 and has held it in 2 quarters since.
  • 461 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2022.

Based on Corient Capital Partners's 13F filing for Q3 2022, filed 14 Nov 2022.